Ruth A. Karron
Research Subjects
Research Interests
Ruth A. Karron has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Elizabeth A. Schappell
Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
1 shared publication - Fatimah S. Dawood
Coronavirus and Other Respiratory Viruses Division, Centers for Disease Control and Prevention, Atlanta, Georgia
1 shared publication Maria Deloria Knoll
Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
1 shared publicationMaria Garcia Quesada
Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
1 shared publication- Marissa K. Hetrich
Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA
1 shared publication Nicole Doria-Rose
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland, USA
1 shared publication
Latest Publications
- Open Access
- 22 April 2022
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 7 (8)
Binding and neutralizing antibody responses to SARS-CoV-2 in very young children exceed those in adults
Background: SARS-CoV-2 infections are frequently milder in children than adults, suggesting that immune responses may vary with age. However, information is limited regarding SARS-CoV-2 immune responses in young children. Methods: We compared receptor binding domain–binding antibody (RBDAb) titers and SARS-CoV-2–neutralizing antibody titers, measured by pseudovirus-neutralizing antibody assay in serum specimens obtained from children aged 0–4 years and 5–17 years and in adults aged 18–62 years at the time of enrollment in a prospective longitudinal household study of SARS-CoV-2 infection. Results: Among 56 seropositive participants at enrollment, children aged 0–4 years had more than 10-fold higher RBDAb titers than adults (416 vs. 31, P < 0.0001) and the highest RBDAb titers in 11 of 12 households with seropositive children and adults. Children aged 0–4 years had only 2-fold higher neutralizing antibody than adults, resulting in higher binding-to-neutralizing antibody ratios compared with adults (2.36 vs. 0.35 for ID 50 , P = 0.0004). Conclusion: These findings suggest that young children mount robust antibody responses to SARS-CoV-2 following community infections. Additionally, these results support using neutralizing antibody to measure the immunogenicity of COVID-19 vaccines in children aged 0–4 years. Funding: CDC (award 75D30120C08737).
- 22 April 2022
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 7 (8)
Open AccessBinding and neutralizing antibody responses to SARS-CoV-2 in very young children exceed those in adults
Background: SARS-CoV-2 infections are frequently milder in children than adults, suggesting that immune responses may vary with age. However, information is limited regarding SARS-CoV-2 immune responses in young children. Methods: We compared receptor binding domain–binding antibody (RBDAb) titers and SARS-CoV-2–neutralizing antibody titers, measured by pseudovirus-neutralizing antibody assay in serum specimens obtained from children aged 0–4 years and 5–17 years and in adults aged 18–62 years at the time of enrollment in a prospective longitudinal household study of SARS-CoV-2 infection. Results: Among 56 seropositive participants at enrollment, children aged 0–4 years had more than 10-fold higher RBDAb titers than adults (416 vs. 31, P < 0.0001) and the highest RBDAb titers in 11 of 12 households with seropositive children and adults. Children aged 0–4 years had only 2-fold higher neutralizing antibody than adults, resulting in higher binding-to-neutralizing antibody ratios compared with adults (2.36 vs. 0.35 for ID 50 , P = 0.0004). Conclusion: These findings suggest that young children mount robust antibody responses to SARS-CoV-2 following community infections. Additionally, these results support using neutralizing antibody to measure the immunogenicity of COVID-19 vaccines in children aged 0–4 years. Funding: CDC (award 75D30120C08737).